Compare American Superconductor Corporation (AMSC) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Superconductor Corporation vs Davita Inc — how do they compare? American Superconductor Corporation trades at $32.75 (market cap $1.50B), while Davita Inc trades at $178.34 (market cap $11.72B). The key difference: Davita Inc is far larger — about 7.8× American Superconductor Corporation's market cap, and Davita Inc is trading nearer its 52-week high, American Superconductor Corporation nearer its low. Which is the better fit depends on your goals.
| AMSC | DVA | |
|---|---|---|
Market Cap | $1.50B | $11.72B |
Sector | Technology | Health |
52-Week High | $66.68 | $240.96 |
52-Week Low | $25.95 | $103.87 |
Enterprise Value | $1.36B | $24.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMSC trades at $32.77, down 0.41% with bearish technical signals including RSI overbought conditions and negative cash flow trends. The company reported strong revenue growth of 30% year-over-year in Q1 2026 to $94.1 million but faces margin pressure, with earnings missing estimates. Record orders above $130 million and a $400 million backlog provide visibility, though valuation metrics show mixed signals with a reasonable P/E of 10.06 but elevated EV/EBITDA of 63.13.
Outlook remains cautiously optimistic given strong order pipeline and exposure to energy infrastructure growth, particularly in grid solutions and data center markets. Key risks include margin compression from cost pressures and execution challenges in integrating recent growth. Analyst consensus leans bullish with 53% buy ratings, but investors should monitor Q3 earnings delivery and cash flow improvement for sustained upside.
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Superconductor Corporation
AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.
Read more on AMSC →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
